Dundee says $2 bucksDundee is publishing a New Idea of Interest report on Medicago (MDG-V), highlighting a major upcoming
milestone for the company: first in man results for its lead tobacco-produced H5N1 pandemic flu vaccine. We
believe there is a good probability that Medicago will report positive industry-competitive results, with a moderate
chance that results will be class-leading. If results are competitive, based on comparable companies analysis, we
believe MDG shares would increase to the C$1.15 range which would give Medicago a market capitalization of
C$104 million ($181 million f.d.).
Clearly class-leading results (see "Metrics for Phase I" section later in this report)
could push MDG to $2.00 per share or higher.
Pl
ease click on the link below to open the full multi-page report and printable version.
https://research.dundeesecurities.com/Research/MDG102809.pdf